Charming Medical’s MCTA Shares Soar 54% on Nasdaq Debut After $6.4M IPO

Introduction

Charming Medical Limited (Nasdaq: MCTA) is a Hong Kong-based provider of Traditional Chinese Medicine (TCM)–inspired wellness and beauty services. The company's offerings target women's health across various life stages, combining traditional practices such as herbal therapy, acupuncture, and moxibustion with modern delivery channels. On October 21, 2025, Charming Medical commenced trading on the Nasdaq Capital Market under the ticker symbol MCTA.

Corporate Structure and Operations

Charming Medical operates through a network of subsidiaries in Hong Kong, where it runs four "Beauty Lab" wellness centers. These centers provide therapies including womb-warming treatment, pelvic detox protocols, acupuncture-inspired prenatal massage, and traditional abdominal binding. The company also markets TCM-inspired consumables such as herbal uterine care patches and probiotic intimate wash products. Kit Wong serves as Chief Executive Officer and Chairman of the Board. Employee counts and detailed management bios have not been publicly disclosed.

Traditional Chinese Medicine by Katherine Hanlon

Recent Developments

• On September 30, 2025, the SEC declared effective Charming Medical's Form F-1 registration statement (File No. 333-287258), which enabled a public offering.
• On October 20, 2025, the company filed Form 8-A12B to register its Class A ordinary shares with a par value of $0.0001 for listing on the Nasdaq.
• On October 21, 2025, Charming Medical priced an initial public offering of 1,600,000 Class A shares at $4.00 per share, with underwriters granted a 45-day option to purchase up to an additional 240,000 shares. The offering is expected to generate gross proceeds of approximately $6.4 million (or $7.36 million if the over-allotment option is fully exercised).
• Cathay Securities, Inc. acted as the lead underwriter, with legal counsel from Ortoli Rosenstadt LLP (U.S.), Harney Westwood & Riegels (BVI), and Fairbairn Catley Low & Kong (Hong Kong). Kaufman & Canoles, P.C. served as U.S. counsel to the underwriters.

Financial and Strategic Analysis

For the twelve months ended December 31, 2024, Charming Medical reported revenue of $6.22 million, an increase of 3.43% from $6.02 million in 2023, and net income of $1.20 million, a 54.16% increase year-over-year. Key financial metrics (trailing twelve months) include:

• Profit margin: 19.27%
• Return on assets: 19.53%
• Total cash (most recent quarter): $2.94 million
• Total debt-to-equity (most recent quarter): 2,356.96%
• Levered free cash flow: $884,070

Proceeds from the offering are intended for geographic expansion, potential strategic investments and acquisitions, enhanced research and development, and general working capital. At the close of trading on October 21, 2025, MCTA shares were priced at $6.1632, reflecting a 54.08% increase from the IPO price, on a volume of 506,965 shares.

Market Position and Industry Context

Charming Medical occupies a niche within the wellness and beauty sector by focusing on women's health through TCM methodologies. Its Beauty Lab centers address conditions such as premenstrual syndrome, dysmenorrhea, and menopausal care. The company competes with both local spa and beauty chains in Hong Kong and international wellness brands that offer specialized women’s health services. Industry trends indicate growing consumer interest in holistic and non-pharmaceutical health solutions, which may support Charming Medical's expansion objectives.

tl;dr

Charming Medical Limited began trading on Nasdaq under MCTA on October 21, 2025, following an IPO of 1.6 million shares at $4.00 each. The offering, effective per SEC notice on September 30, 2025, may raise up to $7.36 million if over-allotment shares are sold. Proceeds will support expansion, R&D, and working capital. On day one, shares closed at $6.1632, representing a 54.08% increase. Future outlook is contingent upon the exercise of the over-allotment option and execution of growth initiatives.